Liraglutide in Combination with Metformin in Young Diabetes Patients

A study published online in The New England Journal of Medicine compared the efficacy and safety of liraglutide as an add-on therapy to metformin versus placebo in children and adolescents with type 2 diabetes mellitus (T2DM). The first 26 weeks were a double-blind period, during which patients (aged between 10 and 16 years) were randomized 1:1 to receive subcutaneous liraglutide (up to 1.8 mg/day) or placebo. All patients received metformin. This was followed by a 26-week open-label extension period. The primary endpoint was 26-week change in glycated hemoglobin level. A total of 134 patients received at least one dose of liraglutide (n = 66) or placebo (n = 68). After 26 weeks, the liraglutide group had a mean 0.64 percentage point decrease in glycated hemoglobin level, compared to a 0.42 percentage point increase in the placebo group—a -1.06 percentage-point difference. By week 52, this increased to a -1.30 percentage-point difference. Reported rates of adverse events were similar between the groups, but the liraglutide group had a higher rate of gastrointestinal adverse events.

Source: Tamborlane WV, Barrientos-Pérez M, Fainberg U, et all. N Engl J Med. 2019;doi: 10.1056/NEJMoa1903822